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Abstract
Renal cell carcinoma (RCC) accounts for approximately 2.6% of all cancers in the United States.
While early stage disease is curable by surgery, the median survival of metastatic disease is only 13
months. In the last decade, there has been considerable progress in understanding the genetics of
RCC. The VHL tumor suppressor gene is inactivated in the majority of RCC cases. The VHL protein
(pVHL) acts as an E3 ligase that targets HIF-1, the hypoxia inducible transcription factor, for
degradation by the ubiquitin proteasome system (UPS). In RCC cases with mutant pVHL, HIF-1 is
stabilized and aberrantly expressed in normoxia, leading to the activation of pro-survival genes such
as vascular endothelial growth factor (VEGF). This review will focus on the defect in the UPS that
underlies RCC and describe the development of novel therapies that target the UPS.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Role of the ubiquitin proteasome pathway in 
renal cancer
Each year in the United States, there are approximately
36,000 new cases of renal cell carcinoma (RCC) and
13,000 related deaths (statistics available at http://
www.kidneycancer.org) [1]. Though there are different
pathologic subtypes, the majority (~75%) of RCC cases
are referred to as “conventional” or “clear cell” type
(CCRCC) [1]. Greater than 95% of clear cell kidney can-
cers occur sporadically within the population, while the
remainder occur as part of relatively rare, inherited genetic
syndromes including von Hippel-Lindau disease and
familial clear cell renal cancer [1,2]. The primary genetic
defect of clear cell kidney cancer (in both sporadic and
hereditary forms) involves inactivation of the VHL gene
pathway. Individuals with VHL disease harbor a germline
mutation in one allele of the VHL gene and somatic inac-
tivation of the remaining wild-type allele results in tumor
development [3]. In sporadic CCRCC, somatic inactiva-
tion of the VHL gene also occurs in greater than 60% of
cases via mutation, deletion or methylation-associated
silencing [3-9]. VHL thus represents a classic tumor sup-
pressor gene that is inactivated in CCRCC according to
Knudsen's “two-hit” hypothesis [10,11]. Indeed, loss of
VHL occurs at a very early stage in kidney cancer progres-
sion, suggesting that VHL represents the “gatekeeper” gene
in this malignancy [12].
For decades preceding the modern era of genetics, sur-
geons and pathologists had described the richly vascular
nature of RCC. When the VHL gene was originally identi-
fied in 1993, however, its function was not easily deduced
from its structure because the amino acid sequence of the
protein (pVHL) did not share any significant homology to
other known proteins at the time [13]. It was subse-
quently discovered, however, that pVHL negatively regu-
lates hypoxia-inducible genes such as vascular endothelial
growth factor (VEGF) and erythropoietin (EPO) in renal
cancer cell lines in vitro[14,15]. Normally, hypoxia-induc-
ible genes such as VEGF are expressed at low or undetect-
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able levels under normoxic conditions but are markedly
induced under hypoxic conditions. In pVHL-deficient
renal cancers, there is constitutive upregulation of hypoxic
genes (including VEGF, erythopoietin and carbonic anhy-
drases) in normoxia [16-19]. Over the next decade,
detailed biochemical, structural and functional analyses
of pVHL identified its essential role as part of a multipro-
tein E3 ubiquitin ligase that targets specific proteins for
destruction via the ubiquitin proteasome system (UPS)
[3,15,20-23].
The UPS functions within normal cells of higher eukaryo-
tes in two major ways: 1) as part of a degradative pathway
that regulates the intracellular breakdown of proteins and
2) as part of a non-degradative pathway that regulates the
location and activity of diverse cellular proteins [24-27].
The UPS is an integral part of normal cellular functions
including cell cycle progression, signal transduction,
response to extracellular stress and DNA repair (reviewed
in 26) [26]. In addition, proteins that could be harmful to
the cell, such as damaged, misfolded or misassembled
proteins are also degraded [28].
The mechanism for proteolysis by the UPS is highly regu-
lated and involves several steps that depend on ubiquitin,
a 76 amino acid protein that is highly conserved among
higher eukaryotes [29]. In the first step, the proteolysis
pathway is initiated by a ubiquitin activating enzyme (E1)
that uses ATP to form a high-energy thiolester bond with
the C-terminus of ubiquitin [30]. In the second step, acti-
vated ubiquitin is transferred to a ubiquitin conjugating
enzyme (E2) [31]. In the third step, ubiquitin is subse-
quently conjugated to target proteins in a process medi-
ated by an E3 ubiquitin ligase [32]. The E3 ligase serves as
an adaptor molecule that interacts with both the target
protein and the E2, resulting in formation of an isopep-
tide bond between the C-terminus of ubiquitin and an ε-
amino group of lysine residues in the target protein. Suc-
cessive transfers of activated ubiquitin to lysine-48 of the
previously conjugated ubiquitin molecule lead to the for-
mation of polyubiquitin chains [33,34], which serve as
recognition markers for the 26S proteasome [35] (Figure
1).
Conversely, while the UPS degradative pathway involves
polyubiquitylation of target proteins for degradation, the
non-degradative UPS pathway generally involves monou-
biquitylation of proteins [36,37]. Proteins can be modi-
fied on a single lysine with a single ubiquitin moiety or
modified on multiple lysines with a single ubiquitin moi-
ety (multi-monoubiquitylation). Examples of monoubiq-
uitylation function include translocation of
monoubiquitylated p53 to the mitochondria, endocytosis
of monoubiquitylated receptor tyrosine kinases and acti-
vation of monoubiquitylated transcription factors [38-
40].
The 26S proteasome is a ~2.5 MDa complex composed of
a single core catalytic 20S particle capped on each end by
a 19S particle [24]. The 20S particle is a barrel shaped
structure comprised of four stacked rings, two outer α
rings and two identical inner β rings. Each α and β ring is
in turn composed of seven distinct subunits. The 20S par-
ticle has proteolytic sites facing the interior chamber of
the barrel that are accessible via a narrow pore opening at
either side [41]. Folded proteins, however, cannot access
these pores, so native proteins have to be processed prior
to degradation. Processing occurs via the 19S particle,
which is comprised of at least 17 proteins ranging in
molecular weight from 25 to 100 kDa. The 19S particle
provides multiple functions necessary for binding,
unfolding and processing of protein substrates prior to
entry and degradation within the 20S particle [42,43]. In
addition, the 19S particle contains six different ATPases
that harvest the energy required for proteolysis [44].
The eukaryotic 20S particle contains chymotrypsin-,
trypsin-, and caspase-like proteolytic enzyme activity [45-
47]. Studies utilizing specific chemical inhibitors suggest
that the chymotrypsin-like activity is the most important
of the three enzyme activities for proteolysis [48]. In the
final step of proteolysis, polyubiquitylated target proteins
bind to the 19S particle where they are deubiquitylated,
unfolded, delivered into the catalytic core of the 20S par-
ticle and degraded to peptides 3–22 amino acids in size
[49,50]. The ubiquitin moieties are recycled for subse-
quent reactions.
Interestingly, the ubiquitin system is hierarchical: a single
E1 enzyme can activate a larger number of E2s and each
E2 can interact with one to several E3 proteins that ulti-
mately tag the protein for degradation [51,52]. Some E3
ligases are single polypeptides, while others exist as multi-
protein complexes. Although the absolute number of E3
ligases in mammalian cells remains to be determined, at
least several hundred E3 ligases at the end of this enzy-
matic cascade are thought to confer specificity to the UPS
[52].
Using biochemical methods, a link between pVHL and
the cellular ubiquitylation machinery was made, sup-
ported by the discovery that pVHL exists in a complex
with Elongin B, Elongin C, Cul2 and Rbx1 [53-55]. This
complex closely resembles SCF complexes in yeast that
contain homologues including Skp1 (Elongin C), Cdc53
(Cul2), and Roc1 (Rbx1). In yeast, the SCF complex tar-
gets proteins for ubiquitin-mediated proteasomal degra-
dation and the F-box component (Roc1) confers substrate
specificity. Subsequent functional studies supported theBMC Biochemistry 2007, 8(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/8/S1/S4
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notion that the pVHL–Elongin B–Elongin C–Cul-2–Rbx1
complex functions as an E3 ligase [20-22]. While there is
little sequence homology between pVHL and an F-box
protein, both have an overall pattern of hydrophobic
amino acids that appears to be important for target sub-
strate recognition [56]. These seminal observations subse-
quently led to the important discovery that pVHL binds to
HIFα proteins and targets them for ubiquitin-mediated
proteolysis [15].
In hypoxia, one of three HIFα proteins (Hif1α, Hif2α or
Hif3α) associates with Hif1β to form a heterodimeric
transcription factor (HIF-1) that binds to a consensus
hypoxia-responsive element (HRE; 5'-RCTGTG-3') and
activates a number of (greater than 60) different target
genes involved in diverse biologic processes including
angiogenesis, cell cycle control, proliferation and energy
metabolism (reviewed in 57) [57]. While Hif1β is consti-
tutively expressed, HIFα levels are tightly regulated in
response to changes in oxygen tension. Under hypoxic
conditions, pVHL does not bind to HIFα proteins, which
then accumulate and bind to Hif1β to activate transcrip-
tion. When cells are shifted to normoxia, however, HIFα
proteins instantaneously undergo a post-translational
modification resulting in hydroxylation of crucial proline
residues within regions of HIFα called oxygen-dependent
The ubiquitin proteasome system Figure 1
The ubiquitin proteasome system. In step 1, ubiquitin is activated by a ubiquitin activating enzyme, E1. In step 2, activated 
ubiquitin is transferred to a ubiquitin conjugating enzyme, E2. In step 3, ubiquitin is subsequently conjugated to target proteins 
in a process mediated by an E3 ubiquitin ligase. In step 4, the polyubiquitylated substrate protein is degraded by the 26S protea-
some. A single E1 enzyme can transfer ubiquitin to all of the E2s in the cell, and each of the E2s associates with a restricted set 
of E3s that confer substrate specificity.BMC Biochemistry 2007, 8(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/8/S1/S4
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degradation domains (ODDs) [23,58,59]. Hydroxylation
results in a change in conformation of the HIFα proteins,
which permits binding to and degradation by pVHL.
Interestingly, hydroxylation of HIFα proteins is per-
formed by a conserved family of prolyl-4 hydroxylases
that require oxygen for activity, suggesting that these
enzymes contribute to oxygen sensing [60,61].
X-ray crystallographic analysis of pVHL has revealed two
major protein domains: an α domain and a β domain.
The surface of the α domain (residues 155–192) is prima-
rily responsible for the interaction between pVHL and
Elongin C [56]. The surface of the β domain consists of a
seven-stranded β sandwich (residues 63–154) and an α
helix (residues 193–204), and is primarily responsible for
binding to HIFα proteins. In sporadic RCC, about one
half of VHL gene mutations map to the α domain and the
other half to the β domain. The majority of these muta-
tions (http://www.cancerindex.org/geneweb/VHL.htm)
are missense mutations and many lead to aberrant upreg-
ulation of HIF-1, either by abolishing binding of pVHL to
Elongin C and/or to HIFα proteins (reviewed in 3)
[3,62,63]. In patients with inherited VHL disease, RCC
tumors harbor VHL deletions or truncation mutations,
also leading to aberrant upregulation of HIF-1. Taken
together, these observations support a genotype-pheno-
type link in RCC, since the hypervascularity of these
tumors can be explained by a pVHL-dependent defect in
ubiquitin-mediated degradation of HIFα proteins, lead-
ing to increased HIF-1 transcriptional activity with conse-
quent upregulation of VEGF and other factors that are
thought to promote survival (reviewed in 57) [57,64-66]
(Figure 2).
Models for studying RCC
Most of the data described above linking pVHL function
to the UPS was obtained from studies conducted in vitro.
Evidence for this model evolved and converged over time
from a variety of disciplines including biochemistry, struc-
tural biology and molecular genetics. Invaluable insights
were gained from studies of yeast, Drosophila, Caenorhab-
ditis elegans and human RCC cell lines [20,54,67-69]. Our
understanding of the genotype-phenotype link in RCC is
based on a thorough analysis of VHL mutations found in
primary human kidney tumors [63].
Historically, there has been considerable difficulty in
establishing relevant animal models for RCC. VHL-/- mice
(created by the Linehan laboratory, National Cancer Insti-
tute, USA) die during early embryogenesis due to defec-
tive placental vasculogenesis [70]. VHL+/- heterozygous
mice (created by the Walker laboratory, University of
Texas M.D. Anderson Cancer Center, USA) are prone to
vascular proliferative lesions of the liver but do not
develop kidney tumors [71]. Rodents exposed to carcino-
gens can develop kidney tumors; however, the genetic
defect involves the tumor suppressor gene Tsc-2 (tuberous
sclerosis complex-2) rather than VHL and the animals dis-
play chromophilic rather than clear cell histology [71].
Interestingly, though, Tsc-2 mutant tumors, like VHL
mutant tumors, are highly vascular and express very high
levels of HIF-1 [72].
Several studies have generated mice with human RCC cell
line-derived xenograft tumors, injected either subcutane-
ously or orthotopically into the kidney [69,73-75]. While
animal models have a limited capacity to recapitulate the
tumor biology of humans, they have permitted controlled
experiments both for the analysis of renal tumorigenesis
and the evaluation of novel therapeutics for RCC. For
example, when pVHL function is restored to renal cancer
cell lines lacking pVHL, these cells lose the capacity to
form tumors in mice in vivo[69]. However, when these
same pVHL-restored RCC cells are engineered to express a
stable Hif2α variant lacking its prolyl hydroxylation/
pVHL binding sites, they regain their ability to form
tumors in vivo[76]. These data underscore the importance
of HIF-1 signaling in VHL-derived tumorigenesis.
Disease targets and ligands
The Food and Drug Administration recently approved two
new agents for the treatment of advanced kidney cancer:
Sutent (Sunitinib, SU011248, manufactured by Pfizer)
and Nexavar (Sorafenib, Bay 43-9006, manufactured by
Bayer Pharmaceuticals and Onyx). Both agents are small
molecule tyrosine kinase inhibitors that block receptor
signaling by primarily targeting VEGF and platelet-derived
growth factor (PDGF) [77]. It appears, however, that other
tyrosine kinases are targeted, for example c-Kit, which is
inhibited by Sutent [78]. The aggregate effect of these
drugs is to inhibit angiogenesis, although direct effects on
cell proliferation may also be important. Along with Avas-
tin (Bevacizumab, manufactured by Genentech), the anti-
VEGF antibody, these agents demonstrate the therapeutic
benefit of inhibiting angiogenesis in RCC [79].
The discovery that the primary genetic event in CCRCC
(loss of VHL) results in a defect in the UPS suggests that
novel therapies targeting this pathway could be employed
to induce apoptosis in cancer cells. Importantly, trans-
formed cells generally display increased susceptibility to
apoptosis by proteasome inhibitors when compared with
non-transformed cells [80]. The basis for this is under
investigation, but possible explanations include stabiliza-
tion of proteins that normally either contribute to apop-
tosis (for example p53, p21, p27, Bax and Smac/Diablo)
or that antagonize pro-survival pathways (for example
Iκβ, proteasomal stabilization of which inhibits nuclear
translocation of NFκβ, a proto-oncogenic transcription
factor) [81].BMC Biochemistry 2007, 8(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/8/S1/S4
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Model for the E3 ligase function of pVHL in normoxia Figure 2
Model for the E3 ligase function of pVHL in normoxia. A In normal cells, HIFα proteins are hydroxylated by prolyl-4 
hydroxylases (PHDs) that require oxygen for activity. pVHL, in a complex with multiple proteins including Elongin C and Cul-2, 
binds to hydroxylated HIFα proteins and delivers them to the 26S proteasome for destruction. B In RCC, VHL gene mutations 
often disrupt pVHL–HIFα binding and/or the pVHL–Elongin C–Cul-2 complex. The consequence is that stable HIFα proteins 
dimerize with Hif1β and the resulting HIF-1 complex binds to a hypoxia-response element (HRE) to activate pro-survival 
genes, such as VEGF, EPO and Glut1.BMC Biochemistry 2007, 8(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/8/S1/S4
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The discovery of drugs that inhibit the UPS is proceeding
rapidly. To consider their potential use in RCC, it is help-
ful to discuss them based on the component of the UPS
they target.
Inhibitors of the 26S proteasome
Bortezomib (Velcade, manufactured by Millennium Phar-
maceuticals) is a dipetidyl boronic acid that reversibly
inhibits the chymotryspin-like activity found within the
20S particle of the proteasome [82]. Bortezomib has
already been established as an effective agent in the treat-
ment of multiple myeloma [83]. The drug causes apopto-
sis of kidney cancer cell lines in vitro, but was less
promising in two Phase II clinical trials [84-86]. A study
from Memorial Sloan-Kettering reported four partial
responses from a total group of 37 RCC patients treated
(25 clear cell, six papillary, one collecting duct and one
medullary), with clear cell histology present in three of the
four responders [85]. A study from the University of Chi-
cago reported one partial response in a patient with clear
cell histology from a total group of 21 RCC patients
treated (histologic subtypes were not fully reported) [86].
Toxicities attributed to bortezomib (including fatigue,
sensory neuropathy, nausea, anemia and transaminitis)
probably reflect the consequences of nonspecific inhibi-
tion of the UPS. While neither study supported the use of
bortezomib as a single therapeutic agent in patients with
metastatic kidney cancer, the possibility of combining it
with other agents in the future could still be theoretically
desirable, since proteasome inhibition can enhance
chemotherapy and overcome drug resistance in preclini-
cal models [80,87].
Inhibitors of E3 ubiquitin ligases
As described above, E3 ubiquitin ligases are very specific
in their interaction with protein substrates. Therefore,
they are attractive targets for drug discovery since their
inhibition would be expected to have fewer “off-target”
effects and less toxicity than inhibitors of the 26S protea-
some. The interaction between the p53 tumor suppressor
gene and its E3 ligase, MDM2, provides an illustration of
this concept. The p53 tumor suppressor pathway is inacti-
vated in the majority of human tumors. Approximately
50% of all human tumors contain mutations in the p53
gene and the remainder (with wild-type p53) display per-
turbations in p53 signaling due to increased proteasomal
degradation of p53 [88]. Increased proteasomal degrada-
tion of p53 occurs because of increased expression of
MDM2, or alternatively, loss of Arf, an inhibitor of the
p53–MDM2 interaction.
The Nutlins (cis-imidazoline derivatives, available from
Sigma) are small molecule inhibitors of MDM2 that were
discovered in a chemical library screen [89]. Structurally,
the Nutlins occupy the p53 binding site of MDM2,
thereby displacing p53 and preventing its destruction
[90]. Increased levels of p53 then restore tumor suppres-
sor function. The potential for Nutlins (which are orally
bioavailable) as anti-cancer agents is now being explored
in pre-clinical studies. Importantly, in tumor xenografts
derived from a human osteosarcoma cell line, Nutlins
suppressed tumor growth with minimal toxicity to nor-
mal tissues [91].
Development of small molecules that affect the pVHL–
HIFα interaction is also a theoretic possibility. However, a
conceptual dilemma immediately presents itself. In the
case of p53 and MDM2, the UPS defect is inappropriately
increased degradation of p53, with both proteins in their
wild-type conformation. In the case of pVHL and HIFα,
the UPS defect is inappropriately decreased degradation of
HIFα due to mutant pVHL. In the case of p53–MDM2, the
goal of a small molecule is to inhibit binding of p53 to
MDM2. By contrast, in the case of pVHL–HIFα, the goal
would be to promote binding of a mutant form of pVHL to
HIFα. Drugs that promote, rather than inhibit, protein–
protein interactions are extremely difficult to design and
screen for. In addition, given the large number of VHL
mutations that would presumably result in different con-
formations of pVHL, the development of small molecule
agonists to promote a mutant pVHL–HIFα association
would in reality be unfeasible.
Activators of the 26S proteasome
Since loss of pVHL E3 ligase function leads to impaired
ubiquitylation and protein degradation in RCC, the devel-
opment of drugs that activate proteasome function would
theoretically be of interest [92]. However, a potential lim-
itation of this strategy would be the requirement that such
drugs enhance degradation of non-ubiquitylated proteins.
While such non-specific “panactivators” of proteasome
function have not been described, drugs are being devel-
oped that can promote ubiquitin-mediated proteasomal
degradation of HIFα subunits in pVHL-deficient RCC.
Inhibitors of Hsp90
Hsp90 is described as a “super-chaperone machine”
because it normally associates with certain proteins to
promote their proper folding so that they can respond to
a stimulus (e.g. cytosolic kinase) or bind to a ligand (e.g.
a steroid hormone) [93]. Hsp90 also functions to stabilize
certain proteins from proteasomal degradation. In some
cases, Hsp90 stabilizes proteins that function as onco-
genes in tumorigenesis, examples of which include the
p210Bcr-Abl protein in chronic myelogenous leukemia,
HER-2 in breast and prostate cancer, and Hif1α [94-98].
Importantly, small molecule inhibitors of Hsp90 promote
degradation of HIFα proteins in a pVHL-independent
manner [99,100]. Interestingly, this process involves
ubiquitylation of HIFα subunits via a mechanism thatBMC Biochemistry 2007, 8(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/8/S1/S4
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does not involve proline hydroxylation [99]. Several
Phase I and/or Phase II studies are being conducted in the
United States testing the Hsp90 inhibitor 17-DMAG (17-
N-Allylamino-17-Demethoxygeldanamycin, available
from A.G. Scientific) in patients with RCC (see http://
www.cancer.gov/clinicaltrials).
Inhibitors of mTOR
The mTOR (mammalian target of rapamycin) signaling
pathway has been shown to enhance HIF-1 activity in
response to growth factors [101,102]. Inhibitors of the
mTOR pathway, such as rapamycin, reduce HIF-1 levels
and HIF-1 transcriptional activity. The mechanism of the
suppressive effect of rapamycin on HIF-1 activity is due to
increased degradation of HIFα proteins by the UPS [103].
Early clinical trials have shown that the novel mTOR
inhibitor CCI779 (temsirolimus, Torisel, manufactured
by Wyeth Pharmaceuticals), has promising activity in
patients with advanced RCC [104,105].
Future directions in the treatment of RCC
Continued efforts to identify drugs that activate the pro-
teasome pathway rather than inhibit it would address the
fact that the primary UPS defect in RCC is its downregula-
tion rather than upregulation. Upregulation of the UPS
system has been reported in other cancer types and has
been offered as one reason why these cancers are more
susceptible than normal cells to apoptosis induced by
proteasome inhibitors [80,87]. While drugs that specifi-
cally target HIF-1 degradation exist, there have been no
reports to date of compounds that generally increase pro-
tein turnover by the UPS. Since the pVHL E3 ligase com-
plex targets proteins other than HIFα, for example atypical
protein C, such compounds would be an interesting con-
cept [106].
A major obstacle in treating advanced RCC tumors (i.e.
those not cured by surgery) has been their resistance to
most standard chemo- and radio- therapies. The reasons
for this are unclear, though possibilities include the com-
plex genetics of the tumor, defective angiogenesis and
tumor hypoxia. Even Sutent and Nexavar, which have
upstaged low-dose immunotherapy in the treatment of
this disease, are predominantly tumoristatic rather than
tumoricidal. Thus, there is considerable room for
improvement in treating RCC. One prediction is that
combinations of two or more drugs will likely be neces-
sary to approach any possibility of a cure. As an example,
it makes biologic sense that the combination of a drug
that blocks VEGF receptor signaling, an Hsp90 inhibitor
and a DNA damaging agent could synergistically promote
apoptosis in RCC. However, the exact combination of
drugs and the ability to administer them safely to human
patients remains a daunting challenge.
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